Healthcare provider profile · identity verified

Gregory L Hall, MD

Allopathic & Osteopathic Physicians|Family Medicine · DONALSONVILLE, GA · NPI 1295815215

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Gregory L Hall, MD received $94.93 in general payments during 2025 across 5 reported records.

Novo Nordisk Inc accounted for 38.5% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 6 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Trelegy Ellipta.

AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Farxiga by this doctor in 2024.

AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Symbicort by this doctor in 2024.

GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trelegy Ellipta by this doctor in 2024.

Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Ozempic by this doctor in 2024.

Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tresiba as an associated drug or biological on 415 records involving 264 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Tresiba by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$94.93

5 reported records · 4 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Novo Nordisk Inc	Unresolved — no canonical attribution shown	$36.55	38.5%	2	2025
Kowa Pharmaceuticals America, Inc.	Unresolved — no canonical attribution shown	$24.42	25.7%	1	2025
AstraZeneca Pharmaceuticals LP	Unresolved — no canonical attribution shown	$18.36	19.3%	1	2025
GlaxoSmithKline, LLC.	Unresolved — no canonical attribution shown	$15.60	16.4%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$94.93	5

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
ZORYVE Normalized: zoryve	Drug	Kowa Pharmaceuticals America, Inc.	$24.42	1	2025
Source payment records 2025-11-19 · Kowa Pharmaceuticals America, Inc. · $24.42 · Open Payments source
Wegovy Normalized: wegovy	Drug	Novo Nordisk Inc	$19.44	1	2025
Source payment records 2025-07-15 · Novo Nordisk Inc · $19.44 · Open Payments source
AIRSUPRA Normalized: airsupra	Drug	AstraZeneca Pharmaceuticals LP	$18.36	1	2025
Source payment records 2025-06-10 · AstraZeneca Pharmaceuticals LP · $18.36 · Open Payments source
Ozempic Normalized: ozempic	Drug	Novo Nordisk Inc	$17.11	1	2025
Source payment records 2025-05-21 · Novo Nordisk Inc · $17.11 · Open Payments source
Rybelsus Normalized: rybelsus	Drug	Novo Nordisk Inc	$17.11	1	2025
Source payment records 2025-05-21 · Novo Nordisk Inc · $17.11 · Open Payments source
TRELEGY ELLIPTA Normalized: trelegy ellipta	Drug	GlaxoSmithKline, LLC.	$15.60	1	2025
Source payment records 2025-02-26 · GlaxoSmithKline, LLC. · $15.60 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
Ozempic ozempic	2025	Ozempic	2024	126	exact normalized	Medicare Part D
TRELEGY ELLIPTA trelegy ellipta	2025	Trelegy Ellipta	2024	14 Beneficiary count suppressed	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference	2025	FARXIGA open payments reported associated product	CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362	Farxiga · 2024 Exact normalized brand match · 1 Part D row	20	suppressed by CMS
AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference	2025	SYMBICORT open payments reported associated product	CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610	Symbicort · 2024 Exact normalized brand match · 1 Part D row	57	11
GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference	2025	TRELEGY ELLIPTA open payments reported associated product	CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369	Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row	14	suppressed by CMS
Novo Nordisk Inc Exact reporting entity; no affiliate inference	2025	Ozempic open payments reported associated product	CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076	Ozempic · 2024 Exact normalized brand match · 1 Part D row	126	25
Novo Nordisk Inc Exact reporting entity; no affiliate inference	2025	Tresiba open payments reported associated product	CMS Open Payments — General Payments 415 supporting records · 264 recipient NPIs · example record 1188130328	Tresiba · 2024 Exact normalized brand match · 1 Part D row	15	suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Levothyroxine Sodium	Levothyroxine Sodium	819	140
Atorvastatin Calcium	Atorvastatin Calcium	781	174
Pantoprazole Sodium	Pantoprazole Sodium	691	137
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	613	102
Amlodipine Besylate	Amlodipine Besylate	506	114
Potassium Chloride	Potassium Chloride	475	97
Losartan Potassium	Losartan Potassium	434	99
Gabapentin	Gabapentin	422	81
Furosemide	Furosemide	379	95
Alprazolam	Alprazolam	343	50
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	298	84
Simvastatin	Simvastatin	285	63
Lisinopril	Lisinopril	265	68
Tramadol Hcl	Tramadol Hcl	262	63
Metformin Hcl	Metformin Hcl	259	60
Tamsulosin Hcl	Tamsulosin Hcl	255	67
Metoprolol Tartrate	Metoprolol Tartrate	254	44
Omeprazole	Omeprazole	237	64
Montelukast Sodium	Montelukast Sodium	230	45
Chlorthalidone	Chlorthalidone	229	59
Clopidogrel	Clopidogrel Bisulfate	229	54
Glimepiride	Glimepiride	228	48
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	226	31
Sertraline Hcl	Sertraline Hcl	209	34
Celecoxib	Celecoxib	208	53
Metoprolol Succinate	Metoprolol Succinate	205	57
Allopurinol	Allopurinol	201	52
Mounjaro	Tirzepatide	192	28
Carvedilol	Carvedilol	191	36
Fluticasone Propionate	Fluticasone Propionate	187	79
Zolpidem Tartrate	Zolpidem Tartrate	173	37
Eliquis	Apixaban	167	24
Albuterol Sulfate Hfa	Albuterol Sulfate	160	47
Trazodone Hcl	Trazodone Hcl	158	28
Xarelto	Rivaroxaban	154	27
Metformin Hcl Er	Metformin Hcl	140	33
Meloxicam	Meloxicam	138	28
Temazepam	Temazepam	137	27
Famotidine	Famotidine	130	29
Ozempic	Semaglutide	126	25
Rosuvastatin Calcium	Rosuvastatin Calcium	125	29
Methocarbamol	Methocarbamol	123	33
Pregabalin	Pregabalin	123	30
Paroxetine Hcl	Paroxetine Hcl	122	18
Tizanidine Hcl	Tizanidine Hcl	121	29
Hydrochlorothiazide	Hydrochlorothiazide	118	33
Prednisone	Prednisone	117	59
Bumetanide	Bumetanide	116	15
Citalopram Hbr	Citalopram Hydrobromide	115	26
Duloxetine Hcl	Duloxetine Hcl	113	21
Escitalopram Oxalate	Escitalopram Oxalate	113	21
Lorazepam	Lorazepam	112	23
Donepezil Hcl	Donepezil Hcl	107	18
Isosorbide Mononitrate Er	Isosorbide Mononitrate	107	20
Fluoxetine Hcl	Fluoxetine Hcl	106	18
Digoxin	Digoxin	103	suppressed
Nebivolol Hcl	Nebivolol Hcl	103	29
Jardiance	Empagliflozin	102	19
Alendronate Sodium	Alendronate Sodium	100	23
Diclofenac Sodium	Diclofenac Sodium	94	29
Atenolol	Atenolol	88	19
Aripiprazole	Aripiprazole	85	suppressed
Pravastatin Sodium	Pravastatin Sodium	84	22
Ciprofloxacin Hcl	Ciprofloxacin Hcl	81	65
Quetiapine Fumarate	Quetiapine Fumarate	75	11
Entresto	Sacubitril/Valsartan	73	15
Topiramate	Topiramate	70	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	69	16
Mirtazapine	Mirtazapine	68	14
Clonazepam	Clonazepam	66	12
Hydralazine Hcl	Hydralazine Hcl	66	13
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	65	22
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	64	54
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	62	12
Baclofen	Baclofen	61	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	61	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	60	12
Venlafaxine Hcl Er	Venlafaxine Hcl	59	13
Ropinirole Hcl	Ropinirole Hcl	57	suppressed
Symbicort	Budesonide/Formoterol Fumarate	57	11
Divalproex Sodium	Divalproex Sodium	55	suppressed
Linzess	Linaclotide	55	15
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	55	41
Synthroid	Levothyroxine Sodium	55	suppressed
Breztri Aerosphere	Budesonide/Glycopyr/Formoterol	53	suppressed
Finasteride	Finasteride	53	suppressed
Fluconazole	Fluconazole	53	39
Azithromycin	Azithromycin	49	34
Ondansetron Hcl	Ondansetron Hcl	49	18
Myrbetriq	Mirabegron	48	15
Oxybutynin Chloride	Oxybutynin Chloride	48	suppressed
Memantine Hcl	Memantine Hcl	47	14
Glipizide Er	Glipizide	45	11
Ondansetron Odt	Ondansetron	45	20
Meclizine Hcl	Meclizine Hcl	44	18
Sucralfate	Sucralfate	44	14
Ipratropium-Albuterol	Ipratropium/Albuterol Sulfate	43	suppressed
Tresiba Flextouch U-100	Insulin Degludec	43	suppressed
Warfarin Sodium	Warfarin Sodium	42	suppressed
Benazepril Hcl	Benazepril Hcl	41	suppressed
Lovastatin	Lovastatin	40	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	39	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	39	11
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	39	suppressed
Promethazine Hcl	Promethazine Hcl	39	11
Levetiracetam	Levetiracetam	37	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	36	suppressed
Fenofibrate	Fenofibrate	35	suppressed
Trulicity	Dulaglutide	35	suppressed
Glipizide	Glipizide	34	suppressed
Latanoprost	Latanoprost	34	suppressed
Terazosin Hcl	Terazosin Hcl	34	suppressed
Nifedipine Er	Nifedipine	33	suppressed
Buspirone Hcl	Buspirone Hcl	32	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	32	suppressed
Primidone	Primidone	32	suppressed
Ramipril	Ramipril	32	11
Tradjenta	Linagliptin	32	suppressed
Vascepa	Icosapent Ethyl	32	suppressed
Verapamil Er	Verapamil Hcl	32	suppressed
Colchicine	Colchicine	31	13
Livalo	Pitavastatin Calcium	31	suppressed
Sotalol	Sotalol Hcl	30	suppressed
Torsemide	Torsemide	30	suppressed
Clonidine Hcl	Clonidine Hcl	29	suppressed
Ezetimibe	Ezetimibe	29	suppressed
Levofloxacin	Levofloxacin	28	23
Bupropion Hcl Sr	Bupropion Hcl	27	suppressed
Novolin 70-30	Insulin Nph Hum/Reg Insulin Hm	27	suppressed
Oxcarbazepine	Oxcarbazepine	27	suppressed
Diazepam	Diazepam	26	suppressed
Spironolactone	Spironolactone	26	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	26	21
Bupropion Xl	Bupropion Hcl	25	suppressed
Januvia	Sitagliptin Phosphate	25	suppressed
Levemir Flexpen	Insulin Detemir	25	suppressed
Tresiba Flextouch U-200	Insulin Degludec	25	suppressed
Cilostazol	Cilostazol	24	suppressed
Dexlansoprazole Dr	Dexlansoprazole	24	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	23	suppressed
Estradiol	Estradiol	23	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	23	suppressed
Ventolin Hfa	Albuterol Sulfate	23	11
Cephalexin	Cephalexin	22	19
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	22	16
Farxiga	Dapagliflozin Propanediol	20	suppressed
Cyanocobalamin Injection	Cyanocobalamin (Vitamin B-12)	19	suppressed
Haloperidol	Haloperidol	19	suppressed
Lithium Carbonate	Lithium Carbonate	19	suppressed
Fentanyl	Fentanyl	18	suppressed
Folic Acid	Folic Acid	18	suppressed
Spiriva Handihaler	Tiotropium Bromide	18	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	17	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	17	15
Mupirocin	Mupirocin	17	11
Nitroglycerin	Nitroglycerin	17	13
Phenytoin Sodium Extended	Phenytoin Sodium Extended	17	suppressed
Ranolazine Er	Ranolazine	17	suppressed
Amoxicillin	Amoxicillin	16	13
Breo Ellipta	Fluticasone/Vilanterol	16	suppressed
Clindamycin Hcl	Clindamycin Hcl	16	12
Enalapril Maleate	Enalapril Maleate	16	suppressed
Nystatin	Nystatin	16	suppressed
Terbinafine Hcl	Terbinafine Hcl	16	suppressed
Zypitamag	Pitavastatin Magnesium	16	suppressed
Clonidine	Clonidine	15	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	15	suppressed
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	15	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	15	suppressed
Methimazole	Methimazole	15	suppressed
Premarin	Estrogens, Conjugated	15	suppressed
Propranolol Hcl	Propranolol Hcl	15	suppressed
Sildenafil Citrate	Sildenafil Citrate	15	suppressed
Tresiba	Insulin Degludec	15	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	15	suppressed
Autoshield Duo Pen Needle	Pen Needle,dual Safety,diabetc	14	suppressed
Brimonidine Tartrate	Brimonidine Tartrate	14	suppressed
Ibuprofen	Ibuprofen	14	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	14	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	14	11
Acarbose	Acarbose	13	suppressed
Butalb-Acetaminoph-Caff-Codein	Butalbit/Acetamin/Caff/Codeine	13	suppressed
Levemir	Insulin Detemir	13	suppressed
Methadone Hcl	Methadone Hcl	13	suppressed
Nadolol	Nadolol	13	suppressed
Namzaric	Memantine Hcl/Donepezil Hcl	13	suppressed
Toujeo Max Solostar	Insulin Glargine,hum.Rec.Anlog	13	suppressed
Vraylar	Cariprazine Hcl	13	suppressed
Amlodipine-Valsartan	Amlodipine Besylate/Valsartan	12	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	12	suppressed
Dilt-Xr	Diltiazem Hcl	12	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	12	suppressed
Metolazone	Metolazone	12	suppressed
Oseltamivir Phosphate	Oseltamivir Phosphate	12	12
Oxycodone Hcl	Oxycodone Hcl	12	suppressed
Amiodarone Hcl	Amiodarone Hcl	11	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	11	suppressed
Dropsafe Prep Pads	Alcohol Antiseptic Pads	11	suppressed
Incruse Ellipta	Umeclidinium Bromide	11	suppressed
Lubiprostone	Lubiprostone	11	suppressed
Metronidazole	Metronidazole	11	11
Novolin R	Insulin Regular, Human	11	suppressed
Valacyclovir	Valacyclovir Hcl	11	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$94.93 · 5 records	Novo Nordisk Inc	AIRSUPRA, Ozempic, Rybelsus, TRELEGY ELLIPTA, Wegovy, ZORYVE	5	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Ozempic play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error